Related Experiment Video
Updated: Jun 14, 2025
Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
A Multi-Target Pharmacological Correction of a Lipoyltransferase LIPT1 Gene Mutation in Patient-Derived Cellular
David Gómez-Fernández1, Ana Romero-González1, Juan M Suárez-Rivero1
1Centro Andaluz de Biología del Desarrollo (CABD-CSIC-Universidad Pablo de Olavide), 41013 Sevilla, Spain.
Abstract:
Mutations in the lipoyltransferase 1 (LIPT1) gene are rare inborn errors of metabolism leading to a fatal condition characterized by lipoylation defects of the 2-ketoacid dehydrogenase complexes causing early-onset seizures, psychomotor retardation, abnormal muscle tone, severe lactic acidosis, and increased urine lactate, ketoglutarate, and 2-oxoacid levels. In this article, we characterized the disease pathophysiology using fibroblasts and induced neurons derived from a patient bearing a compound heterozygous mutation in LIPT1. A Western blot analysis revealed a reduced expression of LIPT1 and absent expression of lipoylated pyruvate dehydrogenase E2 (PDH E2) and alpha-ketoglutarate dehydrogenase E2 (α-KGDH E2) subunits. Accordingly, activities of PDH and α-KGDH were markedly reduced, associated with cell bioenergetics failure, iron accumulation, and lipid peroxidation. In addition, using a pharmacological screening, we identified a cocktail of antioxidants and mitochondrial boosting agents consisting of pantothenate, nicotinamide, vitamin E, thiamine, biotin, and α-lipoic acid, which is capable of rescuing LIPT1 pathophysiology, increasing the LIPT1 expression and lipoylation of mitochondrial proteins, improving cell bioenergetics, and eliminating iron overload and lipid peroxidation. Furthermore, our data suggest that the beneficial effect of the treatment is mainly mediated by SIRT3 activation. In conclusion, we have identified a promising therapeutic approach for correcting LIPT1 mutations.
Insights
Rare LIPT1 gene mutations cause severe metabolic disorders. A new study identified a vitamin cocktail that rescues LIPT1 pathophysiology by boosting mitochondrial function and reducing cellular damage.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Mutations in the lipoyltransferase 1 (LIPT1) gene cause rare, fatal inborn errors of metabolism.
- These defects lead to lipoylation failure in 2-ketoacid dehydrogenase complexes, resulting in severe neurological and metabolic symptoms.
Purpose of the Study:
- To characterize the pathophysiology of LIPT1 mutations using patient-derived cells.
- To identify a potential therapeutic strategy for LIPT1 deficiency.
Main Methods:
- Utilized fibroblasts and induced neurons from a patient with compound heterozygous LIPT1 mutations.
- Performed Western blot analysis to assess LIPT1 expression and lipoylation.
- Measured enzyme activities (PDH, α-KGDH), cell bioenergetics, iron accumulation, and lipid peroxidation.
- Conducted pharmacological screening to identify therapeutic agents.
Main Results:
- Confirmed reduced LIPT1 expression and absent lipoylation of PDH E2 and α-KGDH E2 subunits.
- Observed impaired enzyme activities, cell bioenergetics failure, iron overload, and lipid peroxidation.
- Identified a cocktail of antioxidants and mitochondrial boosters (pantothenate, nicotinamide, vitamin E, thiamine, biotin, α-lipoic acid) that rescued LIPT1 pathophysiology.
- Demonstrated increased LIPT1 expression, improved lipoylation, enhanced bioenergetics, and reduced cellular damage with the cocktail.
- Showed that the treatment's efficacy is mediated by SIRT3 activation.
Conclusions:
- LIPT1 mutations lead to severe cellular dysfunction due to lipoylation defects.
- A specific combination of vitamins and antioxidants shows promise as a therapeutic approach for LIPT1 deficiency.
- SIRT3 activation appears to be a key mechanism underlying the treatment's beneficial effects.
More Related Videos
10:56A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
09:45Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins and mRNA into Freshly Isolated Primary Mouse Hepatocytes
Published on: June 2, 2022
